Advanced search
Publication Cover
Leukemia & Lymphoma Volume 59, 2018 - Issue 12
Submit an article Journal homepage
502
Views
19
CrossRef citations to date
0
Altmetric
Letter to the Editor

Ibrutinib-associated ventricular arrhythmia in the FDA Adverse Event Reporting System

Connie ChengDivision of Pharmacovigilance, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA; Correspondence[email protected]
,
Daniel WoronowDivision of Pharmacovigilance, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA;
,
Afrouz NayernamaDivision of Pharmacovigilance, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA;
,
Tanya WroblewskiDivision of Hematology Products, Office of Hematology and Oncology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA
&
S. Christopher JonesDivision of Pharmacovigilance, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA;
Pages 3016-3017 | Received 08 Feb 2018, Accepted 11 Mar 2018, Published online: 24 May 2018

Citations (19)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Francesco Paolo Tambaro, Danilo De Novellis & William G Wierda. (2021) The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View. Journal of Experimental Pharmacology 13, pages 923-935.
Read now
Praveen Ramakrishnan Geethakumari & Farrukh Awan. (2020) An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia. Expert Review of Hematology 13:10, pages 1039-1046.
Read now
Constantine S. Tam & Jennifer R. Brown. (2018) Vigilance for ibrutinib-associated ventricular arrhythmias: rare but be aware. Leukemia & Lymphoma 59:12, pages 2767-2768.
Read now

Articles from other publishers (16)

Anastasia Stella Perpinia, Nikolaos Kadoglou, Maria Vardaka, Georgios Gkortzolidis, Apostolos Karavidas, Theodoros Marinakis, Chrysostomi Papachrysostomou, Panagiotis Makaronis, Charikleia Vlachou, Marina Mantzourani, Dimitrios Farmakis & Konstantinos Konstantopoulos. (2022) Pharmaceutical Prevention and Management of Cardiotoxicity in Hematological Malignancies. Pharmaceuticals 15:8, pages 1007.
Crossref
Preetesh Jain & Michael L. Wang. (2022) Mantle cell lymphoma in 2022—A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. American Journal of Hematology 97:5, pages 638-656.
Crossref
Chloe Pek Sang Tang, Gregory Y.H. Lip, Terry McCormack, Alexander R. Lyon, Peter Hillmen, Sunil Iyengar, Nicolas Martinez‐Calle, Nilima Parry‐Jones, Piers E.M. Patten, Anna Schuh & Renata Walewska. (2021) Management of cardiovascular complications of bruton tyrosine kinase inhibitors. British Journal of Haematology 196:1, pages 70-78.
Crossref
Xianhuo Wang, Yue Fei, Xia Liu, Tingting Zhang, Wei Li, Xiaohui Jia, Xianming Liu, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Xiubao Ren, Qiongli Zhai, Bin Meng, Lanfang Li & Huilai Zhang. (2021) Bortezomib enhances the anti-cancer effect of the novel Bruton’s tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK. Aging 13:17, pages 21102-21121.
Crossref
Matthew R. Fleming, Ling Xiao, Klarissa D. Jackson, Joshua A. Beckman, Ana BaracJavid J. Moslehi. (2021) Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors. Circulation Research 128:12, pages 1973-1987.
Crossref
David A. Bond & Kami J. Maddocks. (2020) Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma. Hematology/Oncology Clinics of North America 34:5, pages 903-921.
Crossref
Joerg Herrmann. (2020) Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nature Reviews Cardiology 17:8, pages 474-502.
Crossref
Jason T. Romancik & Jonathon B. Cohen. (2020) Management of Older Adults with Mantle Cell Lymphoma. Drugs & Aging 37:7, pages 469-481.
Crossref
Jorge J. Castillo, Joshua N. GustineKirsten Meid, Catherine A. Flynn, Maria G. Demos, Maria L. Guerrera, Cristina Jimenez, Amanda Kofides, Xia Liu, Manit Munshi, Nicholas Tsakmaklis, Christopher J. Patterson, Lian Xu, Guang Yang, Zachary R. Hunter & Steven P. Treon. (2020) Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenström Macroglobulinemia on and off Clinical Trials. HemaSphere 4:3, pages e363.
Crossref
Jordan Gauthier, Alexandre V. Hirayama, Janaki PurusheKevin A. Hay, James Lymp, Daniel H. Li, Cecilia C. S. Yeung, Alyssa SheihBarbara S. PenderReed M. Hawkins, Aesha VakilTinh-Doan PhiRachel N. SteinmetzMazyar ShadmanStanley R. RiddellDavid G. MaloneyCameron J. Turtle. (2020) Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. Blood 135:19, pages 1650-1660.
Crossref
Paolo Bernardeschi, Maria Teresa Pirrotta, Attilio Del Rosso, Giulia Fontanelli & Carlo Milandri. (2019) Sudden ventricular fibrillation and death during ibrutinib therapy—A case report. European Journal of Haematology 103:4, pages 442-443.
Crossref
Joe-Elie Salem, Ali Manouchehri, Marie Bretagne, Bénédicte Lebrun-Vignes, John D. Groarke, Douglas B. Johnson, Tao Yang, Nishitha M. Reddy, Christian Funck-Brentano, Jennifer R. Brown, Dan M. Roden & Javid J. Moslehi. (2019) Cardiovascular Toxicities Associated With Ibrutinib. Journal of the American College of Cardiology 74:13, pages 1667-1678.
Crossref
David A. Bond & Jennifer A. Woyach. (2019) Targeting BTK in CLL: Beyond Ibrutinib. Current Hematologic Malignancy Reports 14:3, pages 197-205.
Crossref
Preetesh Jain & Michael Wang. (2019) Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management. American Journal of Hematology 94:6, pages 710-725.
Crossref
Hirohiko Shibayama, Takanori Teshima, Ilseung Choi, Kiyohiko Hatake, Naohiro Sekiguchi & Nozomi Yoshinari. (2019) Phase I study of ibrutinib in Japanese patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma. Journal of Clinical and Experimental Hematopathology 59:4, pages 179-186.
Crossref
. (2019) Ibrutinib. Reactions Weekly 1737:1, pages 154-154.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.